- DTC Differentiated thyroid cancer, ECOG Eastern Cooperative Oncology Group, n/a Not applicable, NR Not reported, PS Performance status, TKI Tyrosine kinase inhibitor
- Sources: Eisai Ltd. 2017 [24, 26], EPAR for lenvatinib [27, 51] and appendix to Bayer HealthCare 2017 [25]
- Text in bold relates to the most notable differences between placebo arms and shaded cells the most notable differences between trials in any arm